PATENT CLAIM ANALYSIS

Application Number: 16226302
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-05
Patent Classification: ["424", "172100"]

Abstract:
A method of modulating immunity in a mammal is provided by modulating Galectin-9 activity in the mammal. Promoting or enhancing immunity may be effected by activating or stimulating Galectin-9 activity in the mammal, such as by administering a Galectin-9 agonist to the mammal. The agonist may be multimeric, soluble PD-L2 or an agonist antibody that binds Galectin-9. Suppressing or preventing immunity may be achieved by inhibiting or blocking Galectin-9 activity in the mammal, such as by administering an antagonist antibody or antibody fragment that binds Galectin-9 or that prevents or inhibits PD-L2 multimerisation and/or binding to Galectin-9. The aforementioned methods may be suitable for preventing or treating a disease, disorder or condition responsive to modulation of Galectin-9 activity. Also provided is a method of designing, screening, engineering or otherwise producing a Galectin-9 agonist, inhibitor or antagonist that may be useful for modulating immunity by modulating Galectin-9 activity.

Claim (Index 8):
The method of  claim 6 , wherein the multimeric soluble PD-L2 comprises 8 PD-L2 monomers.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 98.0
- Lexical Diversity: 2.38806
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13805030', '13294306', '14333375', '15239524', '15239569']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7301329674150244
- 35 USC 102 Novelty (BERT): 0.5277460539060908
- Combined Prediction Score: 0.709894276064131
- Mean Citation Score: 282.063346
- Max Citation Score: 307.9305
- Similarity Product: 162.3894093414545

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test